Angina

Clinical Trial Finder

Many patients with angina are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Implantable Cardioverter Defibrillator Versus Optimal Medical Therapy In Patients With Variant Angina Manifesting as Aborted Sudden Cardiac Death

Conditions:   Angina Pectoris, Variant;   Sudden Cardiac Death
Interventions:   Device: Implantable Cardioverter Defibrillator;   Drug: Optimal Medical Therapy
Sponsors:   Kee-joon Choi;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified July 2016

Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis

Conditions:   Coronary Artery Disease;   Percutaneous Coronary Intervention;   Acute Coronary Syndrome;   Angina Pectoris
Intervention:   Device: Alpine
Sponsors:   Seoul National University Hospital;   Abbott
Recruiting - verified July 2016

Retrospective Study of Acute Chest Pain in Extremely Critical Condition for More Than Ten Years

Conditions:   Acute Myocardial Infarction;   Pulmonary Embolism;   Aortic Dissection
Intervention:  
Sponsor:   Qilu Hospital
Recruiting - verified July 2016

3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation

Condition:   Coronary Artery Disease
Interventions:   Drug: Aspirin;   Drug: Thienopyridine
Sponsor:   Teikyo University
Not yet recruiting - verified July 2016

Clinical Study of Medicinal Product Cardionat® Using in Health Athlete Volunteers

Conditions:   Stroke, Not Specified as Hemorrhage or Infarction;   Angina Pectoris
Intervention:   Drug: оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
Sponsor:   Burnasyan Federal Medical Biophysical Center
Recruiting - verified April 2016

Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis

Condition:   Stable Angina
Intervention:   Device: Drug-eluting stent
Sponsors:   Seoul National University Hospital;   Ajou University School of Medicine;   Keimyung University Dongsan Medical Center;   Inje University
Recruiting - verified July 2016

Comparative Effectiveness of Decision Aids for Stable Chest Discomfort

Conditions:   Coronary Artery Disease;   Stable Angina
Interventions:   Behavioral: Online decision aid;   Behavioral: Video decision aid
Sponsor:   Massachusetts General Hospital
Active, not recruiting - verified July 2016

Remote Ischaemic Conditioning and Coronary Endothelial Function (RIC-COR)

Conditions:   Ischemic Preconditioning;   Coronary Disease
Interventions:   Procedure: Remote ischaemic conditioning;   Procedure: Arm cuff placement, no inflation;
Sponsors:   NHS National Waiting Times Centre Board;   University of Glasgow;   Chest, Heart and Stroke Association Scotland;   Chief Scientist Office of the Scottish Government
Completed - verified July 2016

Treadmill CV Safety Study

Condition:   Stable Angina
Interventions:   Drug: AMG 334;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified July 2016

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Conditions:   Coronary Artery Disease;   Atherosclerosis, Coronary;   Myocardial Ischemia;   Ischemic Heart Disease;   Acute Coronary Syndrome;   Angina Pectoris
Interventions:   Device: Orsiro DES;   Device: Xience DES
Sponsors:   Biotronik, Inc.;   Biotronik AG;   Harvard Clinical Research Institute;   Medstar Research Institute
Active, not recruiting - verified July 2016

Validation of Simple Acute Coronary Syndrome (SACS) Score

Conditions:   Chest Pain;   Acute Coronary Syndrome;   Angina;   Myocardial Infarction
Intervention:  
Sponsors:   Bayfront Health St Petersburg;   Bayfront Health Dade City;   Community Health Systems (CHS)
Enrolling by invitation - verified July 2016

REPARA Study: REgistry of PAtients With bioResorbable Device in Daily Clinical prActice

Condition:   Coronary Artery Lesions With Implantation of Coronary Device
Intervention:  
Sponsor:   Sección Hemodinamica y Cardiologia Intervencionista
Active, not recruiting - verified July 2016

Diuretic Comparison Project

Condition:   Hypertension
Interventions:   Drug: Hydrochlorothiazide (HCTZ);   Drug: Chlorthalidone
Sponsor:   VA Office of Research and Development
Recruiting - verified July 2016

Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS

Condition:   Non ST Segment Elevation Acute Coronary Syndrome
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   Catholic University of the Sacred Heart
Terminated - verified July 2016

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)

Conditions:   Hypertension;   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified July 2016

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

Condition:   Saphenous Vein Graft Disease
Interventions:   Drug: Aspirin;   Drug: Ticagrelor
Sponsors:   Boca Raton Regional Hospital;   AstraZeneca;   Ottawa Heart Institute Research Corporation
Recruiting - verified July 2016

Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction

Conditions:   Coronary Artery Disease;   Acute Myocardial Infarction With ST-segment Elevation;   Primary Percutaneous Coronary Intervention;   Early Discharge
Interventions:   Other: Early discharge;   Other: Standard discharge
Sponsor:   Kamil Novobílský
Recruiting - verified July 2016

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Active, not recruiting - verified July 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified July 2016

Conservative Non-Invasive Versus Routine Invasive Management in Coronary Artery Bypass Surgery Patients With Non ST Elevation Elevation Acute Coronary Syndrome

Conditions:   Non ST Elevation Myocardial Infarction;   Unstable Angina
Intervention:   Procedure: Invasive management
Sponsors:   NHS National Waiting Times Centre Board;   University of Glasgow
Completed - verified July 2016

Serial EValuation of multiplE Coronary Artery Diseases by an Optical Coherence Tomography; Assessment of the Changes of de Novo Lesions and Comparisons of Neointimal Coverage Between Xience Prime® Versus Cypher SelectTM Stents; SEVEN-Xience Study

Condition:   Multi-vessel Diseases, Angina
Interventions:   Device: Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL);   Device: Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA);   Drug: Pravastatin 20mg;   Drug: Atorvastatin 40mg
Sponsor:   Yonsei University
Completed - verified July 2016

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention &Amp; Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified July 2016

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Active, not recruiting - verified July 2016

Fractional Flow Reserve Versus Angiographically Guided Management to Optimise Outcomes in Unstable Coronary Syndromes

Conditions:   Non-ST Elevation Myocardial Infarction.;   Type 1 Myocardial Infarction.
Intervention:   Device: Fractional flow reserve
Sponsors:   NHS National Waiting Times Centre Board;   British Heart Foundation;   St. Jude Medical;   University of Glasgow
Active, not recruiting - verified July 2016

A Study of Evacetrapib in High-Risk Vascular Disease

Condition:   Cardiovascular Diseases
Interventions:   Drug: Evacetrapib;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   The Cleveland Clinic
Active, not recruiting - verified July 2016

Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents

Condition:   Stable Angina or Acute Coronary Syndrome Considered for Percutaneous Coronary Intervention With Dyslipidemia or Hypertension
Interventions:   Device: Sirolimus-eluting stent;   Device: Biolimus-eluting stents;   Drug: pravastatin 20mg/day after DES implantation;   Drug: pitavastatin 2mg/day after DES implantation;   Drug: Non-ARB /day after DES implantation;   Drug: Eposartan 600mg/day after DES implantation
Sponsor:   Yonsei University
Completed - verified July 2016

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Condition:   Crohn's Disease
Interventions:   Drug: CP-690,550;   Drug: CP-690,550
Sponsor:   Pfizer
Recruiting - verified July 2016

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Condition:   Ankylosing Spondylitis
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified July 2016

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

Conditions:   Atherosclerosis;   Coronary Artery Disease
Interventions:   Drug: RVX000222;   Drug: Placebo
Sponsor:   Resverlogix Corp
Completed - verified July 2016

Cardiac FDG PET Viability Registry

Conditions:   Heart Failure;   Ischemic Heart Disease;   Myocardial Dysfunction
Intervention:  
Sponsors:   Ottawa Heart Institute Research Corporation;   Ontario Ministry of Health and Long Term Care
Recruiting - verified July 2016

CPAP Therapy in Patients With Heart Failure and Obstructive Sleep Apnea.

Conditions:   Heart Failure;   Obstructive Sleep Apnea
Interventions:   Other: Positron Emission Tomography;   Other: Positron Emission Tomography;   Other: Positron Emission Tomography
Sponsors:   Ottawa Heart Institute Research Corporation;   Heart and Stroke Foundation of Ontario
Completed - verified July 2016

PET and Recovery Following Revascularization (PARR 2)

Conditions:   Coronary Artery Disease;   Ventricular Dysfunction, Left
Interventions:   Procedure: Positron emission tomography: FDG viability imaging;   Other: PET imaging
Sponsors:   Ottawa Heart Institute Research Corporation;   Canadian Institutes of Health Research (CIHR);   Heart and Stroke Foundation of Ontario
Completed - verified July 2016

Cardiology Biobank Registry

Condition:   Cardiovascular Disease
Intervention:  
Sponsor:   Emory University
Recruiting - verified July 2016

Non-invasive Diagnosis of Coronary Artery Stenoses by Doppler Echocardiography

Conditions:   Stable Angina Pectoris;   Unstable Angina Pectoris;   Acute Myocardial Infarction
Intervention:   Procedure: Doppler echocardiography
Sponsor:   Norwegian University of Science and Technology
Completed - verified July 2016

Effect of Increased Oxygenation in the Air During Endurance Training in Stable Angina Pectoris Patients

Condition:   Angina Pectoris
Interventions:   Behavioral: Hypoxic interval training;   Behavioral: Normoxic interval training
Sponsors:   Norwegian University of Science and Technology;   Aarhus University Hospital
Completed - verified July 2016